JP2017517506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517506A5 JP2017517506A5 JP2016568497A JP2016568497A JP2017517506A5 JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5 JP 2016568497 A JP2016568497 A JP 2016568497A JP 2016568497 A JP2016568497 A JP 2016568497A JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- heavy chain
- light chain
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001534P | 2014-05-21 | 2014-05-21 | |
| US62/001,534 | 2014-05-21 | ||
| PCT/US2015/031081 WO2015179236A1 (en) | 2014-05-21 | 2015-05-15 | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517506A JP2017517506A (ja) | 2017-06-29 |
| JP2017517506A5 true JP2017517506A5 (enExample) | 2018-07-12 |
Family
ID=53284562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568497A Pending JP2017517506A (ja) | 2014-05-21 | 2015-05-15 | 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10023649B2 (enExample) |
| EP (1) | EP3145956A1 (enExample) |
| JP (1) | JP2017517506A (enExample) |
| KR (1) | KR20170004006A (enExample) |
| CN (1) | CN106413751A (enExample) |
| AU (1) | AU2015264528A1 (enExample) |
| BR (1) | BR112016026993A2 (enExample) |
| CA (1) | CA2949214A1 (enExample) |
| IL (1) | IL248540A0 (enExample) |
| MX (1) | MX2016015181A (enExample) |
| RU (1) | RU2016146993A (enExample) |
| WO (1) | WO2015179236A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120198A1 (en) * | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| CA2955184A1 (en) * | 2016-01-25 | 2017-07-25 | Pfizer Inc. | Combination of an ox40 agonist and a 4-1bb agonist for treating cancer |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US10780080B2 (en) * | 2016-11-23 | 2020-09-22 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| CN112210010B (zh) | 2017-01-06 | 2023-12-05 | 优特力克斯有限公司 | 抗-人4-1bb抗体及其应用 |
| ES2863412T3 (es) * | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| ES3000510T3 (en) | 2017-06-09 | 2025-02-28 | Providence Health & Services Oregon | Tumor-infiltrating t-cells for use in the treatment of cancer |
| AU2018301393B2 (en) * | 2017-07-11 | 2025-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| WO2019072274A1 (zh) * | 2017-10-12 | 2019-04-18 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| CN109651507B (zh) | 2017-10-12 | 2021-11-26 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| EP3706750A1 (en) | 2017-11-06 | 2020-09-16 | RAPT Therapeutics, Inc. | Chemokine receptor modulators for treatment of epstein barr virus positive cancer |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019109238A1 (en) | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| KR20200113228A (ko) * | 2018-01-22 | 2020-10-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도 |
| EP3765489B1 (en) * | 2018-03-13 | 2024-10-16 | F. Hoffmann-La Roche AG | Therapeutic combination of 4-1bb agonists with anti-cd20 antibodies |
| US12054554B2 (en) | 2018-04-10 | 2024-08-06 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| CN112739339B (zh) | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| NZ781538A (en) | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| JP7682102B2 (ja) | 2019-05-10 | 2025-05-23 | リビジェン バイオファーマ ホールディングス リミテッド | ヒト化抗ｃｄ１３７抗体およびその使用 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| AU2021207851A1 (en) * | 2020-01-13 | 2022-07-14 | Cytodyn Inc. | CCR5 binding agent for treatment of CCR5 positive metastatic cancer |
| EP4100059A1 (en) * | 2020-02-04 | 2022-12-14 | Genmab A/S | Antibodies for use in therapy |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CA3198591A1 (en) * | 2020-10-13 | 2022-04-21 | Board Of Regents, The University Of Texas System | Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| US20240277842A1 (en) | 2021-06-07 | 2024-08-22 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US12240910B2 (en) | 2021-07-14 | 2025-03-04 | Genentech, Inc. | Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| CN1296960A (zh) * | 1999-11-22 | 2001-05-30 | 上海博容基因开发有限公司 | 一种新的多肽——人ccr4相关蛋白31和编码这种多肽的多核苷酸 |
| CA2458627C (en) | 2001-08-31 | 2013-09-10 | Kyowa Kirin Co., Ltd. | Human cdr-grafted antibody and antibody fragment thereof |
| US20040109847A1 (en) * | 2002-07-15 | 2004-06-10 | Lieping Chen | Treatment and prophylaxis with 4-1BB-binding agents |
| JPWO2005053741A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬 |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| WO2006055697A2 (en) | 2004-11-17 | 2006-05-26 | Board Of Regents, The University Of Texas System | Cancer immunotherapy incorporating p53 |
| EP2399935A3 (en) * | 2005-02-15 | 2012-02-22 | GTC Biotherapeutics, Inc. | An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| JP2008542354A (ja) | 2005-06-03 | 2008-11-27 | ファイザー・プロダクツ・インク | 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用 |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| MX337040B (es) * | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| SG191716A1 (en) | 2010-11-19 | 2013-08-30 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
-
2015
- 2015-05-15 CN CN201580027437.7A patent/CN106413751A/zh active Pending
- 2015-05-15 WO PCT/US2015/031081 patent/WO2015179236A1/en not_active Ceased
- 2015-05-15 AU AU2015264528A patent/AU2015264528A1/en not_active Abandoned
- 2015-05-15 KR KR1020167035347A patent/KR20170004006A/ko not_active Withdrawn
- 2015-05-15 BR BR112016026993A patent/BR112016026993A2/pt not_active Application Discontinuation
- 2015-05-15 JP JP2016568497A patent/JP2017517506A/ja active Pending
- 2015-05-15 MX MX2016015181A patent/MX2016015181A/es unknown
- 2015-05-15 CA CA2949214A patent/CA2949214A1/en not_active Abandoned
- 2015-05-15 RU RU2016146993A patent/RU2016146993A/ru not_active Application Discontinuation
- 2015-05-15 US US15/312,515 patent/US10023649B2/en not_active Expired - Fee Related
- 2015-05-15 EP EP15727159.4A patent/EP3145956A1/en not_active Withdrawn
-
2016
- 2016-10-27 IL IL248540A patent/IL248540A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017517506A5 (enExample) | ||
| Suurs et al. | A review of bispecific antibodies and antibody constructs in oncology and clinical challenges | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| JP2017516775A5 (enExample) | ||
| MX2024015039A (es) | Composiciones anti-cd24 y usos de las mismas | |
| JP2016041733A5 (enExample) | ||
| JOP20200292A1 (ar) | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان | |
| JP2017048208A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| BRPI0918178A8 (pt) | anticorpos monoclonais para tratamento de câncer | |
| JP2019527706A5 (enExample) | ||
| JP2015214582A5 (enExample) | ||
| JP2017505782A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| WO2017097723A3 (en) | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies | |
| JP2015534578A5 (enExample) | ||
| JP2017530950A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| Lin et al. | Combination treatment including targeted therapy for advanced hepatocellular carcinoma | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2016510028A5 (enExample) | ||
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| JP2016521266A5 (enExample) | ||
| JP2010209081A5 (enExample) |